369 related articles for article (PubMed ID: 17402790)
1. HER-2-positive breast cancer: hope beyond trastuzumab.
Bartsch R; Wenzel C; Zielinski CC; Steger GG
BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
[TBL] [Abstract][Full Text] [Related]
2. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.
Bedard PL; de Azambuja E; Cardoso F
Curr Cancer Drug Targets; 2009 Mar; 9(2):148-62. PubMed ID: 19275756
[TBL] [Abstract][Full Text] [Related]
3. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
4. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Esteva FJ; Pusztai L
Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
[TBL] [Abstract][Full Text] [Related]
5. Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Flaherty KT; Brose MS
Curr Oncol Rep; 2006 Mar; 8(2):90-5. PubMed ID: 16507217
[TBL] [Abstract][Full Text] [Related]
6. Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.
Abramovitz M; Williams C; Loibl S; Leyland-Jones B
Clin Breast Cancer; 2016 Dec; 16(6):444-455. PubMed ID: 27435628
[TBL] [Abstract][Full Text] [Related]
7. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
[TBL] [Abstract][Full Text] [Related]
8. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
10. [New treatment approaches in breast cancer].
Spirig C; Thürlimann B; Huober J
Ther Umsch; 2008 Apr; 65(4):207-10. PubMed ID: 18622912
[TBL] [Abstract][Full Text] [Related]
11. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
12. New insights into anti-HER-2 receptor monoclonal antibody research.
Kumar R; Mandal M; Vadlamudi R
Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
[TBL] [Abstract][Full Text] [Related]
13. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
Nielsen DL; Andersson M
Ugeskr Laeger; 2007 Sep; 169(37):3085-7. PubMed ID: 17877954
[TBL] [Abstract][Full Text] [Related]
14. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Ross JS; Slodkowska EA; Symmans WF; Pusztai L; Ravdin PM; Hortobagyi GN
Oncologist; 2009 Apr; 14(4):320-68. PubMed ID: 19346299
[TBL] [Abstract][Full Text] [Related]
15. HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?
Widakowich C; Dinh P; de Azambuja E; Awada A; Piccart-Gebhart M
Anticancer Agents Med Chem; 2008 Jun; 8(5):488-96. PubMed ID: 18537532
[TBL] [Abstract][Full Text] [Related]
16. [Monoclonal antibodies and breast cancer. Current therapeutic progress].
Collignon J; Gennigens C; Rorive A; Coucke P; Lifrange E; Maweja S; Fillet G; Jerusalem G
Rev Med Liege; 2009; 64(5-6):279-83. PubMed ID: 19642459
[TBL] [Abstract][Full Text] [Related]
17. [Tykerb for breast cancer].
Suzuki Y; Saito Y; Okamura T; Tokuda Y
Gan To Kagaku Ryoho; 2011 Jun; 38(6):892-5. PubMed ID: 21677477
[TBL] [Abstract][Full Text] [Related]
18. EGFR and HER-2 antagonists in breast cancer.
O'Donovan N; Crown J
Anticancer Res; 2007; 27(3A):1285-94. PubMed ID: 17593621
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.
Brandes AA; Franceschi E; Tosoni A; Degli Esposti R
Expert Rev Anticancer Ther; 2010 Feb; 10(2):179-84. PubMed ID: 20131994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]